Analyst Price Target is $45.18
▲ +374.10% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Taysha Gene Therapies in the last 3 months. The average price target is $45.18, with a high forecast of $60.00 and a low forecast of $28.00. The average price target represents a 374.10% upside from the last price of $9.53.
Current Consensus is
The current consensus among 11 investment analysts is to buy stock in Taysha Gene Therapies.
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments; and collaboration with Yale University to advance mini-gene payloads for an AAV gene therapy for the treatment of neurodevelopmental disorders. The company was incorporated in 2019 and is based in Dallas, Texas.